National Hepatobiliary & Enteric Surgery Research Center, Central South University, Changsha, Hunan, 410008, Peoples Republic of China.
Pathol Oncol Res. 2012 Apr;18(2):397-403. doi: 10.1007/s12253-011-9458-8. Epub 2011 Sep 10.
Matrix metalloproteinase-1 (MMP-1) is proposed to be involved in both tumor cell invasion and metastasis. MMP-1 proteolytically activates protease activated receptor-1 (PAR-1), which also plays an important role in tumor development and progression. However, it is currently unknown whether MMP-1 activation of PAR-1 has relevance to the progression of hepatocellular carcinoma (HCC). To address this problem, we investigate the clinicopathological and prognostic value of MMP-1/PAR-1 signaling axis in HCC. Immunohistochemistry assay was used to determine the expression of MMP-1 and PAR-1 proteins in normal and HCC tissues. The correlations of MMP-1 and PAR-1 expression with clinicopathological parameters were assessed by Chi-squared test. Patient survival and their differences were determined by Kaplan-Meier method and log-rank test. Cox regression was adopted for multivariate analysis of prognostic factors. MMP-1 and PAR-1 immunoreactivities were negative or low in normal liver tissues, but high in HCC tissues. PAR-1 expression was significantly correlated with that of MMP-1 (r = 0.896, p < 0.0001). The overexpression of MMP-1 and PAR-1 was significantly associated with recurrence, TNM staging and portal vein invasion of HCC. Patients with high MMP-1 and PAR-1 expression had significantly poorer overall survival (OS) (both P < 0.001) and disease-free survival (DFS) (both P < 0.001) when compared with patients with the low expression of MMP-1 and PAR-1. On multivariate analysis, MMP-1 and PAR-1 expression patterns were found to be independent prognostic factors for OS (both P < 0.001) and DFS (both P < 0.001). Our results suggest for the first time that the MMP-1/PAR-1 signaling axis might be applied as a novel marker for the prediction of recurrence and metastasis potency and a significant indicator of poor prognosis for patients with HCC.
基质金属蛋白酶-1(MMP-1)被认为参与了肿瘤细胞的侵袭和转移。MMP-1 蛋白水解激活蛋白酶激活受体-1(PAR-1),PAR-1 也在肿瘤的发展和进展中发挥重要作用。然而,目前尚不清楚 MMP-1 对 PAR-1 的激活是否与肝细胞癌(HCC)的进展有关。为了解决这个问题,我们研究了 MMP-1/PAR-1 信号轴在 HCC 中的临床病理和预后价值。免疫组织化学检测用于确定 MMP-1 和 PAR-1 蛋白在正常和 HCC 组织中的表达。采用卡方检验评估 MMP-1 和 PAR-1 表达与临床病理参数的相关性。采用 Kaplan-Meier 法和对数秩检验确定患者的生存情况及其差异。采用 Cox 回归进行预后因素的多因素分析。正常肝组织中 MMP-1 和 PAR-1 的免疫活性为阴性或低表达,而 HCC 组织中高表达。PAR-1 的表达与 MMP-1 的表达显著相关(r=0.896,p<0.0001)。MMP-1 和 PAR-1 的过表达与 HCC 的复发、TNM 分期和门静脉侵犯显著相关。与 MMP-1 和 PAR-1 低表达的患者相比,高表达 MMP-1 和 PAR-1 的患者的总生存(OS)(均 P<0.001)和无病生存(DFS)(均 P<0.001)明显较差。多因素分析发现,MMP-1 和 PAR-1 的表达模式是 OS(均 P<0.001)和 DFS(均 P<0.001)的独立预后因素。我们的研究结果首次表明,MMP-1/PAR-1 信号轴可能作为预测 HCC 复发和转移能力以及判断患者预后不良的新型标志物。